

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 April 2022 (07.04.2022)



(10) International Publication Number
WO 2022/072826 A1

(51) International Patent Classification:

A61P 25/16 (2006.01) C07K 14/47 (2006.01)
A61P 25/18 (2006.01) C12N 15/86 (2006.01)

(21) International Application Number:

PCT/US2021/053166

(22) International Filing Date:

01 October 2021 (01.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/087,164 02 October 2020 (02.10.2020) US

(71) Applicant: SANGAMO THERAPEUTICS, INC.
[US/US]; 7000 Marina Boulevard, Brisbane, California
94005 (US).

(72) Inventors: HATAMI, Asa; c/o Sangamo Therapeutics,
Inc., 7000 Marina Boulevard, Brisbane, California 94005
(US). ZEITLER, Bryan; c/o Sangamo Therapeutics, Inc.,
7000 Marina Boulevard, Brisbane, California 94005 (US).
ZHANG, Lei; c/o Sangamo Therapeutics, Inc., 7000 Ma-
rina Boulevard, Brisbane, California 94005 (US). PAS-
CHON, David Emanuel; c/o Sangamo Therapeutics, Inc.,
7000 Marina Boulevard, Brisbane, California 94005 (US).

(74) Agent: LI, Z. Ying et al.; Steptoe & Johnson LLP, 1330
Connecticut Avenue, N.W., Washington, District of Colum-
bia 20036 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: NOVEL ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSING ALPHA-SYNUCLEIN EX-
PRESSION




FIG. 1

(57) Abstract: The present disclosure provides zinc finger fusion proteins that inhibit expression of alpha-synuclein in the nervous system, and methods of using the proteins to treat Parkinsons disease, Lewy body dementia, multiple system atrophy, Alzheimers disease, and other neurodegenerative diseases.

WO 2022/072826 A1